EQS-News: Volta Medical SAS / Key phrase(s): Financing/Personnel
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
05.01.2023 / 09:30 CET/CEST
The issuer is solely accountable for the content material of this announcement.

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

New spherical of financing led by Vensana Capital will assist expertise platform growth and additional validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in bettering catheter ablation for complicated cardiac arrhythmias

Marseille (France), January 5, 2023 – Volta Medical, a pioneering well being expertise firm creating synthetic intelligence (AI) options to help electrophysiologist physicians in treating complicated cardiac arrhythmias reminiscent of atrial fibrillation (AF), at this time introduced €36 million in new Series B funding, bringing the full capital raised to over €70 million.

The funding spherical was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and present investor Gilde Healthcare. The funding will assist speed up new product improvement, assist extra medical trials, put together for full-scale US commercialization, and pursue additional regulatory approvals. The firm’s lead product, VOLTA VX1, is the primary commercially out there AI decision-support software program to assist information physicians with identification and real-time annotation of distinctive abnormalities (so known as “dispersed electrograms“) on 3D anatomical and electrical maps of the center.  This expertise finally could result in optimized catheter-ablation procedures for complicated arrhythmias, together with persistent AF.

“There is a crucial want to enhance precision and consistency in cardiac ablation procedures for sufferers with persistent AF.” mentioned Theophile Mohr Durdez, Volta Medical CEO and co-founder. “With half of those sufferers requiring repeat therapies, clinicians want instruments that allow them to higher perceive the illness and drastically enhance affected person outcomes. We imagine VOLTA’s VX1 has the potential to do exactly that in a constant, reproducible approach. We are most grateful to the groups at Vensana, Lightstone, and Gilde for his or her assist and confidence as we accomplice to additional validate our merchandise and broaden entry to it globally.”

“Volta Medical’s expertise is designed to redefine how electrophysiologists make real-time choices in pinpointing areas related to atrial fibrillation persistence,” mentioned Justin Klein, MD, JD, co-founder and managing accomplice of Vensana Capital. “We applaud the crew’s dedication to validating their merchandise with an funding in a number of top quality medical trials. We are assured that Volta’s revolutionary AI software program will remodel the effectiveness and effectivity of those difficult procedures.”

Volta Medical is also happy to announce the appointment of skilled medical machine govt, John Slump, as CFO of Volta Medical. A seasoned operator within the {industry}, John has a confirmed monitor report as a founder and CFO, main a number of MedTech firms from idea by way of regulatory approvals, business development, and strategic acquisitions. Most not too long ago, he served as CFO of Surgical Innovation Associates, a quickly rising medical machine firm within the reconstructive and cosmetic surgery market that was acquired by Integra LifeSciences. Prior to that, John co-founded FARAPULSE, a medical machine firm in electrophysiology pioneering novel pulsed subject ablation expertise that was acquired in 2021 by Boston Scientific. Previously, John served as CFO of Attune Medical, an rising development medical machine firm commercializing proprietary esophageal temperature administration units in electrophysiology and different surgical markets.

“I’m excited to hitch the Volta Medical crew and am happy with our potential to draw important fairness funding from each new and present traders in an more and more difficult fundraising local weather,” John mentioned. “VOLTA VX1 has the potential to make a significant distinction within the lives of thousands and thousands of individuals with AF, and this Series B Financing will assist to speed up its improvement and adoption nationally and throughout the globe.”

About Volta Medical
Volta Medical is a well being expertise firm creating synthetic intelligence software program options to help cardiac electrophysiologists throughout arrhythmia therapy procedures to enhance medical outcomes for sufferers. Founded by three physicians and an information scientist in 2016 in Marseille, Volta’s overarching purpose is to enhance cardiac arrhythmia administration by creating state-of-the-art, data-driven medical units educated on giant databases of procedural information with the very best requirements of information safety. The firm’s first product, VX1, is a digital AI companion machine and algorithm to help cardiologists with real-time identification of particular irregular electrograms (EGMs), generally known as dispersed EGMs. For extra data, go to the corporate’s web site at www.volta-medical.com.

About Vensana Capital
Vensana Capital is a enterprise capital and development fairness funding agency devoted to partnering with entrepreneurs who search to remodel healthcare with breakthrough improvements in medical expertise. Launched in 2019, Vensana manages $550M in capital and is actively investing in improvement and business stage firms throughout the MedTech sector, together with medical units, diagnostics and information science, life science instruments, digital well being, and tech-enabled providers. Vensana’s funding crew has a historical past of efficiently partnering with administration groups behind industry-leading firms together with Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. Learn extra at www.vensanacap.com.

About Lightstone Ventures
Lightstone Ventures is a world enterprise capital agency investing in biotech and MedTech firms pioneering large concepts poised to remodel affected person outcomes. Lightstone Ventures was based in 2012 to empower visionary entrepreneurs with the sources and operational steering essential to convey their revolutionary therapeutics and applied sciences to the sufferers who want them most. Lightstone Ventures’ funding crew has led offers leading to 19 acquisitions and 20 preliminary public choices over the past 20 years. The agency has places of work in Boston, Mass., Menlo Park, Calif., Dublin, Ireland and Singapore. For extra data, go to www.lightstonevc.com.

About Gilde Healthcare
Gilde Healthcare is a specialised healthcare investor with two fund methods: Venture&Growth and Private Equity. The agency operates out of places of work in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in quick rising, revolutionary firms energetic in (bio)prescription drugs, healthtech and medtech which might be primarily based in Europe and North America. For extra data, please go to www.gildehealthcare.com.

Media Contact
Jeff Martin, VP of Global Marketing
Volta Medical

U.S. Media Contact
Glenn Silver
Finn Partners

05.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely accountable for the content material of this announcement.

The EQS Distribution Services embrace Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Source link

#Volta #Medical #Secures #36M #Series #Funding #Support #Adoption #Software #Cardiac #Ablation #CFO #Introduced

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *